LAUSR

Global phase 3 trials have demonstrated the priority of several next‐generation anaplastic lymphoma kinase‐tyrosine kinase inhibitors (ALK‐TKIs). However, clinical studies are conducted with specific populations that differ from the real world. The study aimed to evaluate the clinical outcomes of alectinib in real‐world settings. Patients with advanced nonsmall‐cell lung cancer (NSCLC) and EML4‐ALK fusion were enrolled from two medical centers between June 2018 and June 2020. The primary endpoints were objective response rate (ORR) and progression‐free survival (PFS) to alectinib. The secondary endpoint was response of brain metastases. The risk factors for disease progression were also investigated. In total, 127 patients with advanced NSCLC were enrolled into this study. Of them, 54.3% received first‐line alectinib. The 1‐ and 2‐year PFS rates were 77.4% and 68.3%, respectively. ORR and disease control rate (DCR) were 53.5% and 91.3%, respectively. Among patients with brain metastases, intracranial ORR and DCR were 63.6% and 88.6%, respectively. In addition, we found that “crizotinib pretreatment”, “liver metastasis” and “TP53 co‐mutation” were individually associated with shorter PFS in alectinib treatment. In conclusion, this study confirms the salient clinical outcomes of alectinib for ALK‐fusion‐driven NSCLC patients with or without brain metastases, adding real‐world evidence to the priority of alectinib in clinical practice.